News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
244 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37190)
2018 (39122)
2019 (51337)
2020 (57666)
2021 (58724)
2022 (53929)
2023 (42567)
2024 (37443)
2025 (33092)
2026 (8667)
Month
January (2794)
February (3040)
March (3567)
April (3109)
May (3537)
June (3472)
July (2691)
August (3172)
September (3382)
October (3298)
November (3733)
December (2588)
Day
1 (201)
2 (230)
3 (246)
4 (177)
7 (255)
8 (244)
9 (226)
10 (211)
11 (142)
13 (1)
14 (230)
15 (257)
16 (153)
17 (152)
18 (97)
21 (137)
22 (152)
23 (132)
28 (195)
29 (152)
30 (143)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
7
8
9
10
11
13
14
15
16
17
18
21
22
23
28
29
30
Biotech Bay
XDx, Inc. Announces Highmark’s Coverage of AlloMap® for Monitoring Heart Transplant Rejection
November 8, 2011
·
1 min read
Career Advice
3 Things Interviewers Look for on a Resume
November 8, 2011
·
2 min read
Drug Development
Boehringer Ingelheim Pharmaceuticals, Inc. Release: BI 201335 Demonstrates Potential toShorten HCV Treatment Duration While Achieving High Sustained Virological Response Rates in Difficult to Treat Patients
November 8, 2011
·
1 min read
Drug Development
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types
November 8, 2011
·
6 min read
Previous
25 of 25